Phase 2 Alopecia Areata Trial, Recruiting NCT07618195 Sponsor: Epibiotech Condition: Alopecia Areata
Back to Alopecia Areata

Phase 2 Alopecia Areata Trial, Recruiting

NCT07618195
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 19 years old or older
  • You have been diagnosed with androgenetic alopecia (a common type of hair loss sometimes called male or female pattern baldness)
  • You are willing to keep the same hairstyle, hair length, and hair color throughout the study
  • You are willing to avoid certain hair products or treatments that are not allowed during the study
  • You are willing to have a small area of your scalp temporarily tattooed and your hair trimmed in that area so photos can be taken to measure hair growth
  • You are willing to sign a consent form agreeing to take part in the study

Who may not be able to join:

  • You have used certain medications or treatments that affect hair growth within a time period set by the study rules (confirm with trial site)
  • You have a scalp condition or hair disorder other than androgenetic alopecia
  • You have an autoimmune disease that affects your scalp or hair (such as alopecia areata — confirm with trial site)
  • You have a significant ongoing health condition affecting your heart, kidneys, hormones, or immune system, or a serious infection
  • You have tested positive for hepatitis B, hepatitis C, HIV, or syphilis
  • You have previously had a hair transplant, stem cell therapy, or gene therapy
  • You have a known allergy or sensitivity to the study treatment or any of the study procedures
  • You are currently pregnant or breastfeeding
  • You have taken part in another clinical trial within a time period set by the study rules (confirm with trial site)
  • The study doctor has determined for any other reason that the study may not be appropriate for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +82-70-4209-0556

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Epibiotech
Registry
ClinicalTrials.gov
Start date
12 January 2026
Est. completion
1 June 2028

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Incidence of Dose-Limiting Toxicities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov